1. Home
  2. AHG vs IRWD Comparison

AHG vs IRWD Comparison

Compare AHG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AHG

Akso Health Group ADS

HOLD

Current Price

$1.44

Market Cap

757.9M

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$4.57

Market Cap

741.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AHG
IRWD
Founded
2013
1998
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
757.9M
741.8M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
AHG
IRWD
Price
$1.44
$4.57
Analyst Decision
Hold
Analyst Count
0
4
Target Price
N/A
$3.68
AVG Volume (30 Days)
8.7K
2.7M
Earning Date
08-14-2025
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.18
Revenue
$14,842,253.00
$338,987,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$37.22
P/E Ratio
N/A
$25.07
Revenue Growth
512.09
N/A
52 Week Low
$0.83
$0.53
52 Week High
$2.10
$5.78

Technical Indicators

Market Signals
Indicator
AHG
IRWD
Relative Strength Index (RSI) 48.25 51.38
Support Level $1.37 $4.42
Resistance Level $1.48 $4.91
Average True Range (ATR) 0.12 0.32
MACD -0.01 -0.09
Stochastic Oscillator 40.70 33.49

Price Performance

Historical Comparison
AHG
IRWD

About AHG Akso Health Group ADS

Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Share on Social Networks: